Skip to main content

Table 12 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the Barthel Index, for the subgroup in Belgium

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
Barthel Index
 Improved 0.54 0.67 0.12 (− 0.21 to 0.45) 0.34 5 40
 No change 0.84 0.84 0.00 (− 0.04 to 0.03) 0.00 37 22
 Worsened 0.80 0.67 − 0.13 (− 0.29 to 0.03) − 0.65 15 20
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
Barthel Index
 Improved 0.63 0.64 0.01 (− 0.09 to 0.11) 0.07 5 20
 No change 0.81 0.81 0.00 (− 0.03 to 0.03) 0.00 37 38
 Worsened 0.75 0.63 − 0.11 (− 0.24 to 0.01) − 0.67 15 33
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large